Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer

European Journal of Cancer

Volumn 45, Issue 7, 2009, Pages 1193-1200

  Engelen, M J A ^a   Snel, B J ^a   Schaapveld, M ^b   Pras, E ^a   de Vries, E G E ^a   Gietema, J A ^a   van der Zee, A G J ^a   Willemse, P H B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

Chemotherapy; Morbidity; Ovarian cancer; Radiotherapy; Survivors; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN;

ABDOMINAL RADIOTHERAPY; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHRONIC DIARRHEA; CONTROLLED STUDY; CYSTITIS; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; ENTERITIS; FEMALE; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEART FAILURE; HEPATOBILIARY DISEASE; HUMAN; HYDRONEPHROSIS; HYPERTENSION; KIDNEY FAILURE; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MORBIDITY; OSTEOPOROSIS; OVARY CANCER; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RADIATION ENTEROPATHY; RAYNAUD PHENOMENON; SENSORY NEUROPATHY; SEXUAL DYSFUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEART DISEASES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MORBIDITY; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64049104188     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.01.006     Document Type: Article

References (27)

1. Cannistra S.A. Cancer of the ovary. New Engl J Med 351 (2004) 2519-2529
2. Dembo A.J., Bush R.S., Beale F.A., et al. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep 63 (1979) 249-254
3. Dembo A.J. Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 22 (1992) 835-845
4. Cardenes H., and Randall M.E. Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions. Semin Radiat Oncol 10 (2000) 61-70
5. Winter-Roach B., Hooper L., and Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer 13 (2003) 395-404
6. Thigpen T. First-line therapy for ovarian carcinoma: what's next?. Cancer Invest 22 Suppl. 2 (2004) 21-28
7. Bookman M.A. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 15 Suppl. 3 (2005) 212-220
8. Trimbos J.B., Parmar M., Vergote I., et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95 (2003) 105-112
9. Trimbos J.B., Vergote I., Bolis G., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 (2003) 113-125
10. Colombo N., Guthrie D., Chiari S., et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95 (2003) 125-132
11. Hepp R., Baeza M.R., Olfos P., and Suarez E. Adjuvant whole abdominal radiotherapy in epithelial cancer of the ovary. Int J Radiat Oncol Biol Phys 53 (2002) 360-365
12. Kaldor J.M., Day N.E., Pettersson F., et al. Leukemia following chemotherapy for ovarian cancer. New Engl J Med 322 (1990) 1-6
13. Travis L.B., Curtis R.E., Boice Jr. J.D., et al. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 56 (1996) 1564-1570
14. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
15. de Vos F.Y., Nuver J., Willemse P.H., et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer 40 (2004) 696-700
16. van Bunningen B., Bouma J., Kooijman C., et al. Total abdominal irradiation in stage I and II carcinoma of the ovary. Radiother Oncol 11 (1988) 305-310
17. DCTD NND. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. 12.12.2003.
18. Chen Y., Trotti A., Coleman C.N., et al. Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys 64 (2006) 1442-1451
19. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
20. Skirnisdottir I., Nordqvist S., and Sorbe B. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?. Oncol Rep 14 (2005) 521-529
21. Raymond E., Drolet Y., Marpeau L., et al. Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 72 (1997) 181-190
22. Dusenbery K.E., Bellairs E.E., Potish R.A., Twiggs L.B., and Boente M.P. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Gynecol Oncol 96 (2005) 307-313
23. Ong K.L., Cheung B.M., Man Y.B., Lau C.P., and Lam K.S. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (2007) 69-75
24. Bentzen S.M., Vaeth M., Pedersen D.E., and Overgaard J. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!. Int J Radiat Oncol Biol Phys 32 (1995) 1531-1534
25. Maduro J.H., Pras E., Willemse P.H., and de Vries E.G. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29 (2003) 471-488
26. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
27. Firat S., Murray K., and Erickson B. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys 57 (2003) 201-207